GlassScriptPhysician profile
Jeffrey G Clark
NPI 1376643247
$2,501.14
in general payments reported to CMS, 2019-2025
33 companies · $245 in 2025
The $245 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $443 · 2020: $292 · 2021: $661 · 2022: $349 · 2023: $240 · 2024: $271 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $756.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $756.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $462.54 | 2019-2024 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $415.09 | 2020-2025 | |
| Janssen Biotech, INC. | $206.44 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $140.48 | 2019-2022 | |
| Procept Biorobotics Corporation | $101.75 | 2024-2025 | Aquabeam System |
| Urovant Sciences INC | $96.34 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $81.17 | 2019-2025 | Adstiladrin |
| Olympus America INC. | $75.43 | 2024-2025 | Itind System |
| Cook Medical LLC | $72.75 | 2020-2024 | Cook |
| Allergan, INC. | $71.14 | 2020-2021 | |
| Urogen Pharma, INC. | $68.51 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $62.38 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $61.44 | 2019-2024 | Lithovue |
| Dendreon Pharmaceuticals LLC | $57.60 | 2019-2025 | Provenge |
| Tolmar, INC. | $57.25 | 2023-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $51.83 | 2020-2022 | |
| Coloplast Corp | $49.57 | 2020-2021 | |
| Teleflex LLC | $47.80 | 2021-2024 | Urolift |
| Amgen INC. | $40.60 | 2021 | |
| Myriad Genetic Laboratories, INC. | $40.07 | 2023-2024 | Prolaris |
| Mission Pharmacal Company | $33.01 | 2020 | |
| Progenics Pharmaceuticals, INC. | $31.21 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $21.65 | 2022 | |
| Accord Healthcare, INC. | $18.95 | 2023 | |
| Hollister Incorporated | $17.36 | 2022 | |
| Axonics, INC. | $17.07 | 2023 | Bulkamid |
| Myovant Sciences INC. | $16.93 | 2021 | |
| Endo Pharmaceuticals INC. | $16.40 | 2019 | |
| Acerus Pharmaceuticals Corporation | $15.31 | 2021 | |
| Dentsply Ih INC. | $14.62 | 2020 | |
| Ambu INC. | $14.05 | 2020 | |
| Photocure INC | $12.31 | 2021 | |
| Pfizer INC. | $12.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.